Clinical Trial Update: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [Phase 3]

View source ↗

Summary

Phase 3 outcomes study evaluating cardiovascular outcomes after acute coronary syndrome during treatment with alirocumab (ODYSSEY Outcomes) has completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Atherosclerotic Cardiovascular Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-03-18